市場調查報告書

細胞、基因治療藥的全球市場:分析與預測 (2019-2025年)

Global Cell and Gene Therapy Market: Focus on Products, Applications, Regions and Competitive Landscape - Analysis and Forecast, 2019-2025

出版商 BIS Research Inc. 商品編碼 900562
出版日期 內容資訊 英文 243 Pages
商品交期: 最快1-2個工作天內
價格
Back to Top
細胞、基因治療藥的全球市場:分析與預測 (2019-2025年) Global Cell and Gene Therapy Market: Focus on Products, Applications, Regions and Competitive Landscape - Analysis and Forecast, 2019-2025
出版日期: 2019年07月25日內容資訊: 英文 243 Pages
簡介

全球細胞、基因治療藥市場規模在2018年估算為10億1,720萬美元,在2019年∼2025年的預測期間中,預測將以36.52%的年複合成長率 (CAGR) 擴大。

本報告提供全球細胞、基因治療藥市場相關調查,市場成長的主要的促進因素、課題、機會,帶來新趨勢的基本結構,各市場區隔的成長預測,主要應用程式與其主要的市場區隔,主要製造商、服務供應商等相關分析。

第1章 調查範圍、手法

第2章 細胞、基因治療藥市場:全球展望

  • 簡介
  • 細胞、基因治療藥和其臨床上的重要性
  • 細胞、基因治療藥的開發、商業化形勢
  • 全球細胞、基因治療藥市場規模
  • 細胞、基因治療藥的法規團體、聯盟所扮演的角色
  • 醫療費償付、市場進入
  • 細胞、基因治療藥市場上主要企業與其貢獻

第3章 全球細胞、基因治療藥市場概要 (潛在市場規模、成長可能性)

  • 細胞、基因治療藥產業
  • 商業性成功的主要的細胞、基因治療藥
  • 潛在市場、成長可能性
  • 北美
  • 歐洲
  • 亞太地區
  • 南美
  • 其他 (RoW)

第4章 產業考察

  • M&A
  • 產品認證
  • 聯盟、合作、合資企業
  • 事業擴張活動、其他
  • 法律上的必要條件、規定

第5章 專利形勢

第6章 細胞、基因治療藥的製造

  • 病毒媒介製造
  • 非病毒媒介製造
  • 細胞、基因治療藥的製造能力:各企業

第7章 市場動態

  • 影響分析
  • 市場成長的推動要素
  • 市場成長的阻礙因素
  • 機會
  • 市場課題

第8章 全球細胞、基因治療藥市場:各產品

  • 治療藥市場
  • 開發平台分析

第9章 全球細胞、基因治療藥市場:各治療等級

  • 罕見疾病
  • 癌症
  • 血液學
  • 心血管
  • 眼科
  • 神經科
  • 其他治療等級

第10章 全球細胞、基因治療藥市場:各地區

  • 概要
  • 北美
  • 歐洲
  • 亞太地區
  • 南美
  • 其他

第11章 競爭情形

  • 市場佔有率分析
  • 成長佔有率分析

第12章 企業簡介

  • 概要
  • Amgen Inc.
  • bluebird bio, Inc.
  • Dendreon Pharmaceuticals LLC.
  • Fibrocell Science, Inc.
  • Human Stem Cells Institute
  • Kite Pharma, Inc.
  • Kolon TissueGene, Inc.
  • Novartis AG
  • Orchard Therapeutics plc.
  • Organogenesis Holdings Inc.
  • Pfizer, Inc.
  • RENOVA THERAPEUTICS
  • Shanghai Sunway Biotech Co., Ltd.,
  • Sibiono GeneTech Co. Ltd.,
  • Spark Therapeutics, Inc.
  • Vericel Corporation
  • ViroMed Co., Ltd.
目錄
Product Code: BH155A

Global Cell and Gene Therapy Market to Grow at a CAGR of 36.52% from 2019-2025

Key Questions Answered in this Report:

  • What are the major market drivers, challenges, and opportunities in the global cell and gene therapy market?
  • What are the underlying structures resulting in the emerging trends within the global cell and gene therapy market?
  • How is each segment of the global cell and gene therapy market expected to grow during the forecast period and what is the estimated revenue to be generated by each of the segments by the end of 2025?
  • What is the expected compound growth rate to be witnessed by the leading players in the market during the forecast period 2019-2025?
  • What are the key applications in global cell and gene therapy market? What are the major segments of these applications?
  • Who are the key manufacturers and service providers in the global cell and gene therapy market, and what are their contributions?

Global Cell and Gene Therapy Market Forecast, 2019-2025

The cell and gene therapy Industry analysis by BIS Research projects the market to grow at a significant CAGR of 36.52% during the forecast period, 2019-2025. The cell and gene therapy market generated $1,017.2 million revenue in 2018, in terms of value.

The cell and gene therapy growth has been primarily attributed to the major drivers in this market such as increasing prevalence of cancer and chronic diseases, rising number of clinical trials for cell and gene therapy, steady investment and consolidation in the cell and gene therapy market and favorable regulatory environment. The market is expected to grow at a significant growth rate due to the opportunities that lie within its domain, which include drug approvals and strong pipeline of cell and gene therapies. However, there are significant challenges which are restraining the market growth. These challenges include high cost of therapy and lack of therapy specific assays.

Expert Quote on the Cell and Gene Therapy Market

"The CAR-TCR drug development field has achieved huge success over the past year with regulatory approval in the U.S., Europe, Japan and Australia proving the potential these drugs have to successfully cure patients around the globe."

Scope of the Market Intelligence on Cell and Gene Therapy Market

The cell and gene therapy market research provides a holistic view of the cell and gene therapy market in terms of various factors influencing it, including regulatory reforms, and technological advancements.

The scope of this report is centered upon conducting a detailed study of the products and services allied with the therapeutics market. In addition, the study also includes exhaustive information on the unmet needs, perception on the new products, competitive landscape, market share of leading manufacturers, growth potential of each underlying sub-segment, and company, as well as other vital information with respect to global cell and gene therapy market.

Market Segmentation

The cell and gene therapy market segmentation (on the basis of cell and gene therapy manufacturing) is further segmented into upstream manufacturing, and downstream manufacturing.

The cell and gene therapy market segmentation (on the basis of product) is segmented into therapeutic market and pipeline analysis.

The cell and gene therapy market segmentation (on the basis of therapeutic class) is segmented into oncology, hematology, cardiovascular, ophthalmology, neurology, and other applications.

Key Companies in the Cell and Gene Therapy Industry

The key manufacturers who have been contributing significantly to the cell and gene therapy market include Amgen Inc., bluebird bio, Inc. Dendreon Pharmaceuticals LLC., Fibrocell Science, Inc., Human Stem Cell Institute, Kite Pharma, Inc., Kolon TissueGene, Inc., Novartis AG, Orchard Therapeutics plc., Organogenesis Holdings Inc., Pfizer, Inc., Spark Therapeutics, Inc., Vericel Corporation, and ViroMed Co., Ltd., among others.

Table of Contents

1 Research Scope and Methodology

  • 1.1 Scope of the Study
  • 1.2 Research Methodology
  • 1.3 Data Sources
  • 1.4 Assumptions and Limitations
  • 1.5 Data and Prediction Modelling

2 Global Cell and Gene Therapy Market: Global Prospective

  • 2.1 Introduction
  • 2.2 Cell and Gene Therapy and Their Clinical Importance
  • 2.3 Cell and Gene Therapy Development and Commercialization Landscape
  • 2.4 Global Cell and Gene Therapy Market Size, 2018-2025
  • 2.5 Role of Regulatory Bodies and Consortium in Cell and Gene Therapy
  • 2.6 Reimbursement and Market Access
  • 2.7 Key Companies in Cell and Gene Therapy Market and their Contributions

3 Global Cell and Gene Therapy Market Overview (Addressable Market Size and Growth Potential), 2018-2025

  • 3.1 Cell and Gene Therapy Industry
  • 3.2 Key Successful Cell and Gene Therapy Commercialization
  • 3.3 Addressable Market and Growth Potential
  • 3.4 North America
  • 3.5 Europe
  • 3.6 Asia-Pacific
  • 3.7 Latin America
  • 3.8 Rest-of-the-World

4 Industry Insights

  • 4.1 Mergers and Acquisitions
  • 4.2 Product Approvals
  • 4.3 Partnerships, Collaborations and Joint Ventures
  • 4.4 Business Expansion Activities and Others
  • 4.5 Legal Requirements and Regulations
    • 4.5.1 Overview of Regulatory Pathway for Cell and Gene Therapy
    • 4.5.2 FDA Expedited Approval Designations
      • 4.5.2.1 Fast Track Designation:
      • 4.5.2.2 Breakthrough Therapy:
      • 4.5.2.3 Accelerated Approval:
      • 4.5.2.4 Priority Review:
      • 4.5.2.5 Regenerative Medicine Advanced Therapy Designation:
    • 4.5.3 Expedited Designation Vs. Traditional Approval Timelines:
    • 4.5.4 Regulatory Challenges:
    • 4.5.5 Successful Regulatory Strategies

5 Patent Landscape

6 Cell and Gene Therapy Manufacturing

  • 6.1 Viral Vector Manufacturing
    • 6.1.1 Upstream Manufacturing
      • 6.1.1.1 Cost Consideration and Timelines
      • 6.1.1.2 Process Design and Regulatory Burdens
      • 6.1.1.3 Other Considerations
      • 6.1.1.4 Viral vector Manufacturing
        • 6.1.1.4.1 Retrovirus
        • 6.1.1.4.2 Lentivirus
        • 6.1.1.4.3 AAV
        • 6.1.1.4.4 Adenovirus
    • 6.1.2 Downstream Manufacturing
      • 6.1.2.1 Viral Vector Manufacturing
        • 6.1.2.1.1 Retrovirus
        • 6.1.2.1.2 Lentivirus
        • 6.1.2.1.3 AAV
        • 6.1.2.1.4 Adenovirus
      • 6.1.2.2 Cost Considerations and Timelines
      • 6.1.2.3 Challenges in Downstream
      • 6.1.2.4 Scale-up of Downstream from Research to Clinical Manufacturing
  • 6.2 Non-Viral Vector Manufacturing
    • 6.2.1 Non-Viral, Plasmid-Free Manufacturing
    • 6.2.2 Plasmid
    • 6.2.3 Naked DNA
    • 6.2.4 Physical-Mediated Methods
  • 6.3 Cell and Gene Therapy Manufacturing Capacity, by Company

7 Market Dynamics

  • 7.1 Impact Analysis
  • 7.2 Market Drivers
    • 7.2.1 Increasing Prevalence of Cancer and Chronic Diseases
    • 7.2.2 Rising Number of Clinical Trials
    • 7.2.3 Steady Investment and Consolidation in the Cell and Gene Therapy Market
    • 7.2.4 Favorable Regulatory Environment
  • 7.3 Market Restraints
    • 7.3.1 Lack of Reliable Vector Production for Cell and Gene Therapy
  • 7.4 Opportunities
    • 7.4.1 Drug Approvals and Strong Pipeline of Cell and Gene Therapies
  • 7.5 Market Challenges
    • 7.5.1 High Cost of Therapy
    • 7.5.2 Lack of Therapy Specific Assays

8 Global Cell and Gene Therapy Market (by Product)

  • 8.1 Therapeutic Market
    • 8.1.1 Yescarta
    • 8.1.2 Provenge
    • 8.1.3 Luxturna
    • 8.1.4 Kymriah
    • 8.1.5 Imlygic
    • 8.1.6 Gintuit
    • 8.1.7 MACI
    • 8.1.8 Laviv
    • 8.1.9 Gendicine
    • 8.1.10 Oncorine
    • 8.1.11 Neovasculgen
    • 8.1.12 Strimvelis
    • 8.1.13 Invossa
    • 8.1.14 Others
  • 8.2 Pipeline Analysis
    • 8.2.1 Phase 1
    • 8.2.2 Phase 2
    • 8.2.3 Phase 3
    • 8.2.4 Phase 4

9 Global Cell and Gene Therapy Market (by Therapeutic Class)

  • 9.1 Rare Diseases
  • 9.2 Oncology
  • 9.3 Hematology
  • 9.4 Cardiovascular
  • 9.5 Ophthalmology
  • 9.6 Neurology
  • 9.7 Other Therapeutic Classes

10 Global Cell and Gene Therapy Market (by Region), 2018-2025 ($Million)

  • 10.1 Overview
  • 10.2 North America
    • 10.2.1 U.S.
      • 10.2.1.1 Approved Products
      • 10.2.1.2 Market Size and Forecast
      • 10.2.1.3 Key Developments
      • 10.2.1.4 Competitive landscape
    • 10.2.2 Canada
      • 10.2.2.1 Approved Products
      • 10.2.2.2 Market Size and Forecast
      • 10.2.2.3 Key Developments
      • 10.2.2.4 Competitive landscape
  • 10.3 Europe
    • 10.3.1 Germany
      • 10.3.1.1 Approved Products
      • 10.3.1.2 Market Size and Forecast
      • 10.3.1.3 Key Developments
      • 10.3.1.4 Competitive landscape
    • 10.3.2 France
      • 10.3.2.1 Approved Products
      • 10.3.2.2 Market Size and Forecast
      • 10.3.2.3 Key Developments
      • 10.3.2.4 Competitive landscape
    • 10.3.3 U.K.
      • 10.3.3.1 Approved Products
      • 10.3.3.2 Market Size and Forecast
      • 10.3.3.3 Competitive landscape
    • 10.3.4 Italy
      • 10.3.4.1 Approved Products
      • 10.3.4.2 Market Size and Forecast
      • 10.3.4.3 Key Developments
    • 10.3.5 Spain
      • 10.3.5.1 Approved Products
      • 10.3.5.2 Market Size and Forecast
      • 10.3.5.3 Key Developments
      • 10.3.5.4 Competitive landscape
    • 10.3.6 The Netherlands
      • 10.3.6.1 Approved Products
      • 10.3.6.2 Market Size and Forecast
      • 10.3.6.3 Key Developments
      • 10.3.6.4 Competitive landscape
    • 10.3.7 Russia
      • 10.3.7.1 Approved Products
      • 10.3.7.2 Market Size and Forecast
      • 10.3.7.3 Competitive landscape
    • 10.3.8 Rest-of-Europe
      • 10.3.8.1 Market Size and Forecast
      • 10.3.8.2 Key Developments
  • 10.4 Asia-Pacific
    • 10.4.1 Japan
      • 10.4.1.1 Approved Products
      • 10.4.1.2 Market Size and Forecast
      • 10.4.1.3 Key Developments
      • 10.4.1.4 Competitive landscape
      • 10.4.1.5 China
      • 10.4.1.6 Approved Products
      • 10.4.1.7 Market Size and Forecast
      • 10.4.1.8 Key Developments
      • 10.4.1.9 Competitive landscape
    • 10.4.2 Australia
      • 10.4.2.1 Approved Products
      • 10.4.2.2 Market Size and Forecast
      • 10.4.2.3 Key Developments
    • 10.4.3 South Korea
      • 10.4.3.1 Approved Products
      • 10.4.3.2 Market Size and Forecast
      • 10.4.3.3 Key Developments
      • 10.4.3.4 Competitive landscape
    • 10.4.4 India
      • 10.4.4.1 Approved Products
      • 10.4.4.2 Market Size and Forecast
      • 10.4.4.3 Competitive landscape
    • 10.4.5 Singapore
      • 10.4.5.1 Approved Products
      • 10.4.5.2 Market Size and Forecast
      • 10.4.5.3 Key Developments
    • 10.4.6 Rest-of-Asia-Pacific
      • 10.4.6.1 Market Size and Forecast
      • 10.4.6.2 Key Developments
  • 10.5 Latin America
    • 10.5.1 Brazil
      • 10.5.1.1 Market Size and Forecast
    • 10.5.2 Mexico
      • 10.5.2.1 Market Size and Forecast
    • 10.5.3 Rest-of-Latin America
      • 10.5.3.1 Market Size and Forecast
  • 10.6 Rest-of-World
      • 10.6.1.1 Market Size and Forecast

11 Competitive Landscape

  • 11.1 Market Share Analysis
  • 11.2 Growth Share Analysis

12 Company Profiles

  • 12.1 Overview
  • 12.2 Amgen Inc.
    • 12.2.1 Company Overview
    • 12.2.2 Role of Amgen Inc. in the Global Cell and Gene Therapy Market
    • 12.2.3 Financials
    • 12.2.4 Key Insights about Financial Health of the Company
    • 12.2.5 SWOT Analysis
  • 12.3 bluebird bio, Inc.
    • 12.3.1 Company Overview
    • 12.3.2 Role of bluebird bio, Inc. in the Global Cell and Gene Therapy Market
    • 12.3.3 Financials
    • 12.3.4 Key Insights about Financial Health of the Company
    • 12.3.5 SWOT Analysis
  • 12.4 Dendreon Pharmaceuticals LLC.
    • 12.4.1 Company Overview
    • 12.4.2 Role of Dendreon Pharmaceuticals LLC. In the Global Cell and Gene Therapy Market
    • 12.4.3 SWOT Analysis
  • 12.5 Fibrocell Science, Inc.
    • 12.5.1 Company Overview
    • 12.5.2 Role of Fibrocell Science, Inc. in the Global Cell and Gene Therapy Market
    • 12.5.3 Key Insights about Financial Health of the Company
    • 12.5.4 SWOT Analysis
  • 12.6 Human Stem Cells Institute
    • 12.6.1 Company Overview
    • 12.6.2 Role of Human Stem Global Cell and Gene Therapy Cell Market
    • 12.6.3 SWOT Analysis
  • 12.7 Kite Pharma, Inc.
    • 12.7.1 Company Overview
    • 12.7.2 Role of Kite Pharma, Inc. in the Global Cell and Gene Therapy Market
    • 12.7.3 Financials
    • 12.7.4 Key Insights about Financial Health of the Company
    • 12.7.5 SWOT Analysis
  • 12.8 Kolon TissueGene, Inc.
    • 12.8.1 Company Overview
    • 12.8.2 Role of Kolon TissueGene, Inc. in the Global Cell and Gene Therapy Market
    • 12.8.3 SWOT Analysis
  • 12.9 Novartis AG
    • 12.9.1 Company Overview
    • 12.9.2 Role of Novartis AG in the Global Cell and Gene Therapy Market
    • 12.9.3 Financials
    • 12.9.4 SWOT Analysis
  • 12.10 Orchard Therapeutics plc.
    • 12.10.1 Company Overview
    • 12.10.2 Role of Orchard Therapeutics plc. In the Global Cell and Gene Therapy Market
    • 12.10.3 Financials
    • 12.10.4 SWOT Analysis
  • 12.11 Organogenesis Holdings Inc.
    • 12.11.1 Company Overview
    • 12.11.2 Role of Organogenesis Holdings Inc. in the Global Cell and Gene Therapy Market
    • 12.11.3 SWOT Analysis
  • 12.12 Pfizer, Inc.
    • 12.12.1 Company Overview
    • 12.12.2 Role of Pfizer, Inc. in the Global Cell and Gene Therapy Market
    • 12.12.3 Financials
    • 12.12.4 Key Insights about Financial Health of the Company
    • 12.12.5 SWOT Analysis
  • 12.13 RENOVA THERAPEUTICS
    • 12.13.1 Company Overview
    • 12.13.2 Role of RENOVA THERAPEUTICS in the Global Cell and Gene Therapy Market
    • 12.13.3 SWOT Analysis
  • 12.14 Shanghai Sunway Biotech Co., Ltd.,
    • 12.14.1 Company Overview
    • 12.14.2 Role of Shanghai Sunway Biotech Co., Ltd., in the Global Cell and Gene Therapy Market
    • 12.14.3 SWOT Analysis
  • 12.15 Sibiono GeneTech Co. Ltd.,
    • 12.15.1 Company Overview
    • 12.15.2 Role of Sibiono GeneTech Co. Ltd., in the Global Cell and Gene Therapy
    • 12.15.3 SWOT Analysis
  • 12.16 Spark Therapeutics, Inc.
    • 12.16.1 Company Overview
    • 12.16.2 Role of Spark Therapeutics, Inc. in the Global Cell and Gene Test Market
    • 12.16.3 Financials
    • 12.16.4 Key Insights about Financial Health of the Company
    • 12.16.5 SWOT Analysis
  • 12.17 Vericel Corporation
    • 12.17.1 Company Overview
    • 12.17.2 Role of Vericel Corporation in the Global Cell and Gene Therapy Market
    • 12.17.3 Financials
    • 12.17.4 Key Insights About Financial Health of the Company
    • 12.17.5 SWOT Analysis
  • 12.18 ViroMed Co., Ltd.
    • 12.18.1 Company Overview
    • 12.18.2 Role of ViroMed Co., Ltd. In the Global Cell and Gene Therapy Market
    • 12.18.3 Financials
    • 12.18.4 SWOT Analysis

List of Tables

  • Table 2.1: Approved gene therapies worldwide, October 2018
  • Table 2.2: Product Class Inclusions in EU and US Regulatory Pathway
  • Table 2.3: Key Market Access Landscape (9 Countries), January 2019
  • Table 2.4: Key Companies in Cell and Gene Therapy Market, 2018
  • Table 3.1: Key Products of Cell and Gene Therapy Market
  • Table 6.1: Key Viral Vectors
  • Table 6.2: Cell and Gene Therapy Manufacturing Capacity, by Company
  • Table 7.1: Impact Analysis
  • Table 7.2: Key Cell and Gene Therapies with FDA Expedited Review
  • Table 8.1: List of key Cell/Gene Therapy Products with Marketing Authorization (MA)
  • Table 8.2: Key Cell and Gene Therapy Drugs in Phase 3, 2018
  • Table 9.1: List of Cell and Gene Therapy Medicines in Development (As of November 2018)
  • Table 10.1: List of Cell and Gene Therapy Products with Marketing Authorization in the European Union by EMA

List of Figures

  • Figure 1: Impact of Market Drivers and Market Challenges on the Global Cell and Gene Therapy Market
  • Figure 2: Global Cell and Gene Therapy Market Snapshot
  • Figure 3: Dominant Segments of the Global Cell and Gene Therapy Market, 2019 and 2025
  • Figure 4: Global Cell and Gene Therapy Market (by Approved Product), 2019 and 2025
  • Figure 5: Global Cell and Gene Therapy Market (by Therapeutic Class), 2019 and 2025
  • Figure 6: Global Cell and Gene Therapy Market (by Region), 2019 and 2025
  • Figure 1.1: Global Cell and Gene Therapy Market Segmentation
  • Figure 1.2: Global Cell and Gene Therapy Market Research Methodology
  • Figure 1.3: Global Cell and Gene Therapy Market Research Methodology Approach
  • Figure 1.4: Primary Research
  • Figure 1.5: Secondary Research
  • Figure 1.6: Data Triangulation
  • Figure 1.7: Bottom-Up Approach (Segment-Wise Analysis)
  • Figure 1.8: Top-Down Approach (Segment-Wise Analysis)
  • Figure 1.9: Assumptions and Limitations
  • Figure 1.10: Considered Factors for Data Prediction and Modelling
  • Figure 2.1: Clinical Trials by Therapeutic Category, Cell and Gene Therapy, 2018
  • Figure 2.2: Global Cell and Gene Therapy Market Size, 2018-2025
  • Figure 3.1: Addressable Market Size of Commercialized Products, 2018
  • Figure 3.2: Addressable Market Size of Commercialized Products, 2025
  • Figure 3.3: North America Cell and Gene Therapy Addressable Market, 2018 and 2025
  • Figure 3.4: Europe Cell and Gene Therapy Addressable Market, 2018 and 2025
  • Figure 3.5: Asia-Pacific Cell and Gene Therapy Addressable Market, 2018 and 2025
  • Figure 3.6: Latin America Cell and Gene Therapy Addressable Market 2019 and 2025
  • Figure 4.1: Product Approvals Share (by Company), January 2016 - April 2019
  • Figure 4.2: Synergistic Activities Share (by Company), January 2016 - April 2019
  • Figure 5.1: Share of Patents (by Ownership), 2016-2019
  • Figure 7.1: Number of Active and Completed Clinical Trials for Cell and Gene Therapy, by Start Date (2014-2018)
  • Figure 8.1: Global Cell and Gene Therapy Market, by Therapeutic Drugs, 2018-2025
  • Figure 8.2: Global Revenue for Yescarta, 2018-2025
  • Figure 8.3: Global Revenue for Provenge, 2018-2025
  • Figure 8.4: Global Revenue for Luxturna, 2018-2025
  • Figure 8.5: Global Revenue for Kymriah, 2018-2025
  • Figure 8.6: Global Revenue for Imlygic, 2018-2025
  • Figure 8.7: Global Revenue for MACI, 2018-2025
  • Figure 8.8: Global Revenue for Gendicine, 2018-2025
  • Figure 8.9: Global Revenue for Oncorine, 2018-2025
  • Figure 8.10: Global Revenue for Neovasculogen, 2018-2025
  • Figure 8.11: Global Revenue for Strimvelis, 2018-2025
  • Figure 8.12: Global Revenue for Invossa, 2018-2025
  • Figure 8.13: Global Revenue for Other Drugs, 2018-2025
  • Figure 8.14: Cell and Gene Therapy Medicines in Development by Disease, 2018
  • Figure 8.15: Cell and Gene Therapy: Breakdown of Pipeline, 2017
  • Figure 8.16: Number of Phase 1 Clinical Trials for Cell and Gene Therapy, 2014-2018
  • Figure 8.17: Number of Phase 2 Clinical Trials for Cell and Gene Therapy, 2014-2018
  • Figure 8.18: Global Cell and Gene Therapy Market, By Late Phase, 2018-2025
  • Figure 9.1: Global Cell and Gene Therapy Market, By Rare Diseases, 2018-2025
  • Figure 9.2: Global Cell and Gene Therapy Market, By Oncology, 2018-2025
  • Figure 9.3: Global Cell and Gene Therapy Market, By Hematology, 2018-2025
  • Figure 9.4: Global Cell and Gene Therapy Market, By Cardiovascular Disease, 2018-2025
  • Figure 9.5: Global Cell and Gene Therapy Market, By Ophthalmology, 2018-2025
  • Figure 9.6: Global Cell and Gene Therapy Market, By Neurology, 2018-2025
  • Figure 9.7: Global Cell and Gene Therapy Market, By Other Therapeutic Class, 2018-2025
  • Figure 10.1: Global Cell and Gene Therapy Market (by Region), 2019 and 2025
  • Figure 10.2: North America Cell and Gene Therapy Market, 2018-2025
  • Figure 10.3: North America-Market Dynamics
  • Figure 10.4: U.S. Cell and Gene Therapy Market, 2018-2025
  • Figure 10.5: Projections of the Older Adult Population in the U.S.: 2020 to 2060 (Million)
  • Figure 10.6: Canada Cell and Gene Therapy Market, 2018-2025
  • Figure 10.7: Europe Cell and Gene Therapy Market, 2018-2025
  • Figure 10.8: Europe-Market Dynamics
  • Figure 10.9: Germany Cell and Gene Therapy Market, 2018-2025
  • Figure 10.10: France Cell and Gene Therapy Market, 2018-2025
  • Figure 10.11: The U.K. Cell and Gene Therapy Market, 2018-2025
  • Figure 10.12: Italy Cell and Gene Therapy Market, 2018-2025
  • Figure 10.13: Spain Cell and Gene Therapy Market, 2018-2025
  • Figure 10.14: The Netherlands Cell and Gene Therapy Market, 2018-2025
  • Figure 10.15: Russia Cell and Gene Therapy Market, 2018-2025
  • Figure 10.16: Rest-of-Europe Cell and Gene Therapy Market, 2018-2025
  • Figure 10.17: Europe Cell and Gene Therapy Market, 2018-2025
  • Figure 10.18: Asia-Pacific Market Dynamics
  • Figure 10.19: Japan Cell and Gene Therapy Market, 2018-2025
  • Figure 10.20: China Cell and Gene Therapy Market, 2018-2025
  • Figure 10.21: Australia Cell and Gene Therapy Market, 2018-2025
  • Figure 10.22: S. Korea Cell and Gene Therapy Market, 2018-2025
  • Figure 10.23: India Cell and Gene Therapy Market, 2018-2025
  • Figure 10.24: Singapore Cell and Gene Therapy Market, 2018-2025
  • Figure 10.25: Rest-of-Asia-Pacific Cell and Gene Therapy Market, 2018-2025
  • Figure 10.26: Latin America Cell and Gene Therapy Market, 2018-2025
  • Figure 10.27: Latin America: Market Dynamics
  • Figure 10.28: Brazil Cell and Gene Therapy Market, 2018-2025
  • Figure 10.29: Mexico Cell and Gene Therapy Market, 2018-2025
  • Figure 10.30: Rest-of-Latin America Cell and Gene Therapy Market, 2018-2025
  • Figure 10.31: Rest-of-World Cell and Gene Therapy Market, 2018-2025
  • Figure 11.1: Market Share Analysis for the Global Cell and Gene Therapy Market, 2018
  • Figure 11.2: Growth Share Matrix for Global Cell and Gene Therapy Market (by Company), 2018
  • Figure 12.1: Total Number of Companies Profiled
  • Figure 12.2: Amgen Inc.: Overall Product Portfolio
  • Figure 12.3: Amgen Inc.: Pipeline Product Portfolio
  • Figure 12.4: Amgen Inc.: Overall Financials, 2016-2018
  • Figure 12.5: Amgen Inc.: Revenue (by Region), 2016-2018
  • Figure 12.6: Amgen Inc.: R&D Expenditure, 2016-2018
  • Figure 12.7: Amgen Inc.: SWOT Analysis
  • Figure 12.8: Pipeline Product Portfolio: bluebird bio, Inc.
  • Figure 12.9: bluebird bio, Inc.: Overall Financials, 2016-2018
  • Figure 12.10: bluebird bio, Inc.: R&D Expenditure, 2016-2018
  • Figure 12.11: bluebird bio, Inc.: SWOT Analysis
  • Figure 12.12: Dendreon Pharmaceuticals LLC: Product Portfolio
  • Figure 12.13: Dendreon Pharmaceuticals LLC.: SWOT Analysis
  • Figure 12.14: Fibrocell Science, Inc.: Overall Product Portfolio
  • Figure 12.15: Fibrocell Science, Inc.: Pipeline Product Portfolio
  • Figure 12.16: Fibrocell Science, Inc.: R&D Expenditure, 2016-2018
  • Figure 12.17: Fibrocell Science, Inc.: SWOT Analysis
  • Figure 12.18: Human Stem Cell Institute: Overall Product Portfolio
  • Figure 12.19: Human Stem Cell Institute: SWOT Analysis
  • Figure 12.20: Kite Pharma, Inc.: Overall Product Portfolio
  • Figure 12.21: Kite Pharma, Inc.: Pipeline Product Portfolio
  • Figure 12.22: Kite Pharma, Inc.: Overall Financials, 2016-2018
  • Figure 12.23: Kite Pharma, Inc.: R&D Expenditure, 2016-2018
  • Figure 12.24: Kite Pharma, Inc.: SWOT Analysis
  • Figure 12.25: Kolon TissueGene, Inc.: Pipeline Product Portfolio
  • Figure 12.26: Kolon TissueGene, Inc.: SWOT Analysis
  • Figure 12.27: Novartis AG: Overall Product Portfolio
  • Figure 12.28: Novartis AG: Pipeline Product Portfolio
  • Figure 12.29: Novartis AG: Overall Financials, 2016-2018
  • Figure 12.30: Novartis AG: Revenue (by Business Segment), 2016-2018
  • Figure 12.31: Novartis AG: SWOT Analysis
  • Figure 12.32: Orchard Therapeutics plc.: Pipeline Product Portfolio
  • Figure 12.33: Orchard Therapeutics plc.: Overall Financials, 2016-2018
  • Figure 12.34: Orchard Therapeutics plc: SWOT Analysis
  • Figure 12.35: Organogenesis Holdings Inc.: Overall Product Portfolio
  • Figure 12.36: Organogenesis Holdings Inc.: SWOT Analysis
  • Figure 12.37: Pfizer, Inc.: Pipeline Product Portfolio
  • Figure 12.38: Pfizer, Inc.: Overall Financials, 2016-2018
  • Figure 12.39: Pfizer, Inc.: Revenue (by Region), 2016-2018
  • Figure 12.40: Pfizer, Inc.: R&D Expenditure, 2016-2018
  • Figure 12.41: Pfizer, Inc.: SWOT Analysis
  • Figure 12.42: RENOVA THERAPEUTICS: Pipeline Product Portfolio
  • Figure 12.43: RENOVA THERAPEUTICS: SWOT Analysis
  • Figure 12.44: Product Portfolio: Shanghai Sunway Biotech Co., Ltd.,
  • Figure 12.45: Shanghai Sunway Biotech Co., Ltd.: SWOT Analysis
  • Figure 12.46: Sibiono GeneTech Co. Ltd.: Overall Product Portfolio
  • Figure 12.47: Sibiono GeneTech Co. Ltd.: SWOT Analysis
  • Figure 12.48: Spark Therapeutics, Inc.: Overall Product Portfolio
  • Figure 12.49: Spark Therapeutics, Inc.: Pipeline Product Portfolio
  • Figure 12.50: Spark Therapeutics, Inc.: Overall Financials, 2015-2017
  • Figure 12.51: Spark Therapeutics, Inc.: R&D Expenditure, 2015-2017
  • Figure 12.52: Spark Therapeutics, Inc.: SWOT Analysis
  • Figure 12.53: Vericel Corporation: Overall Product Portfolio
  • Figure 12.54: Vericel Corporation: Pipeline Product Portfolio
  • Figure 12.55: Vericel Corporation: Overall Financials, 2016-2018
  • Figure 12.56: Vericel Corporation: Revenue (by Product), 2016-2018
  • Figure 12.57: Vericel Corporation: R&D Expenditure (2016-2018)
  • Figure 12.58: Vericel Corporation: SWOT Analysis
  • Figure 12.59: ViroMed Co., Ltd.: Pipeline Product Portfolio
  • Figure 12.60: ViroMed Co: Overall Financials, 2016-2018
  • Figure 12.61: ViroMed Co., Ltd.: SWOT Analysis
Back to Top